Table 1 Clinical course, tumor size, and serum tumor markers
Months | Clinical course | Tumor size (CT) (mm) | Tumor marker | Evaluate the response to treatment | |||||
|---|---|---|---|---|---|---|---|---|---|
S2 | S3 | S5 | S6 | S8 | CEA (ng/mL) | CA19-9 (U/mL) | |||
0 | At diagnosis | 16 | 12 | 12 | 7 | 8 | 6 | 2601 | |
1 | Lower anterior rectal resection | ||||||||
2 | XELOX + Bmab (1st course) | 45.9 | 22,751 | ||||||
5 | XELOX + Bmab (4th course) | 18 | 0 | 0 | 0 | 0 | 5.4 | 515 | PR |
7 | XELOX + Bmab (7th course) | 4.4 | 166 | ||||||
9 | XELOX + Bmab (9th course) | 4.4 | 873 | ||||||
11 | XELIRI + Bmab (1st course) | 21 | 0 | 0 | 0 | 0 | 9.5 | 9027 | SD |
13 | XELIRI + Bmab (4th course) | 43.4 | 42,380 | PD | |||||
14 | Extended left hepatectomy | 46 | 0 | 0 | 0 | 0 | |||
16 | Gemcitabine + TS-1 | 10.9 | 2345 | ||||||